New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
09:18 EDTHDY, IRDM, GOGO, TWTR, BPI, ALNY, HSH, P, CLB, NIHD, SRO, PFOn The Fly: Pre-market Movers
HIGHER: Pinnacle Foods (PF), up 18% after agreeing to be acquired by Hillshire Brands (HSH) for $6.6B. Hillshire Brands is down 1.5% after the news... TESARO (TSRO), up 20% after rolapitant Phase 3 trial meets primary, secondary endpoints... Alnylam (ALNY), up 7.7% after naming new program ALN-HBV to its pipeline. UP AFTER EARNINGS: Gogo (GOGO), up 8.6%. UP AFTER UPGRADES: Pandora (P), up 3.2% after upgraded at MKM Partners... Twitter (TWTR), up 3.1% following upgrade at SunTrust... Peabody (BTU), up 3.8% after upgraded at Morgan Stanley... Iridium (IRDM), up 4% following upgrade at Macquarie. DOWN AFTER EARNINGS: NII Holdings (NIHD), down 10%... Bridgepoint Education (BPI), down 12%... Hyperdynamics (HDY), down 11%. ALSO LOWER: Core Laboratories (CLB), down 12% after lowering earnings outlook.
News For P;TWTR;PF;HSH;GOGO;SRO;ALNY;IRDM;NIHD;BPI;HDY;CLB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
December 10, 2014
11:12 EDTTWTRInstagram announces service now has over 300M users
Subscribe for More Information
09:36 EDTTWTRActive equity options trading
Subscribe for More Information
09:14 EDTPPandora price target lowered to $24 from $30 at Credit Suisse
Credit Suisse lowered Pandora's price target to $24 to reflect marketing spend and platform fees paid out to Google and Apple for Pandora One. Shares are Neutral rated.
December 9, 2014
16:00 EDTTWTROptions Update; December 9, 2014
Subscribe for More Information
12:22 EDTALNYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
09:38 EDTTWTRActive equity options trading
Subscribe for More Information
07:22 EDTPBMO Capital to hold a conference
Subscribe for More Information
06:38 EDTALNYAlnylam to host conference call
Conference call to discuss Phase 1 data from ALN-AT3, in development for the treatment of hemophilia will be held on December 9 at 8 am. Webcast Link
05:47 EDTALNYAlnylam reports poisitve initial results for ALN-AT3
Subscribe for More Information
December 8, 2014
14:24 EDTTWTRRumor: Twitter moves off lows amid speculation Apple may take a stake
Subscribe for More Information
13:38 EDTTWTRTwitter breaks to lows of the day, levels to watch
The shares are down over 6.7% to $35.89 at time of writing. Resistance is now at former support at $36.38. Support is now at $35.06.
11:21 EDTTWTRTwitter volatility low as shares pullback to four-month low
Twitter December weekly call option implied volatility is at 51, December is at 46, January at 43; compared to its 26-week average of 54 according to Track Data, suggesting decreasing price movement
10:46 EDTPPandora calls active on renewed takeover speculation
Subscribe for More Information
10:36 EDTPRumor: Pandora moves up on renewed takeover chatter
10:16 EDTTWTRTwitter falls to session lows, levels to watch
Subscribe for More Information
06:00 EDTTWTRTwitter's former head of product leaving company, Re/code reports
Daniel Graf, who was replaced by Kevin Weil as head of product last month, is leaving the company, Re/code reports. Reference Link
December 7, 2014
13:13 EDTALNYAlnylam files clinical trial application for ALN-CC5
Alnylam Pharmaceuticals announced that it has filed a Clinical Trial Application, CTA, with the U.K. Medicines and Healthcare products Regulatory Agency, MHRA, to initiate a Phase 1/2 clinical trial with ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting complement component C5 for the treatment of complement-mediated diseases. As per the CTA filing, the intended clinical study of ALN-CC5 will be performed in normal human volunteers and, then, in patients with paroxysmal nocturnal hemoglobinuria, PNH. Following approval of the CTA, the company expects to initiate the Phase 1/2 study in early 2015, with initial data expected to be reported in mid-2015. In addition, Alnylam scientists presented new pre-clinical data at the 56th Annual Meeting of the American Society of Hematology. Amongst other reported research findings, new data showed an up to 99.2% knockdown of serum C5 and up to 96.2% inhibition of serum hemolytic activity in non-human primates, NHPs, with continued dosing for over seven months.
December 5, 2014
11:23 EDTTWTROption volume leaders
Subscribe for More Information
08:55 EDTTWTRYahoo seen overtaking Twitter in U.S. mobile ad market share, WSJ reports
Research firm eMarketer predicts Google (GOOG, GOOGL) and Facebook (FB) will account for about 35% and 17%, respectively, of the U.S. mobile ad market in 2015, but the firm also expects Yahoo (YHOO) will edge past Twitter (TWTR) in terms of mobile ad revenue, with projected market shares of 3.74% and 3.69%, respectively, reported The Wall Street Journal. Reference Link
08:39 EDTALNYAlnylam to host research and development day
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use